Inovio Pharmaceuticals Inc.

(INO) Trade

By |

Inovio is revolutionizing the fight against cancers and infectious diseases. We are advancing a broad portfolio of DNA vaccines, also known as immunotherapies, to prevent or treat cancers, HIV, hepatitis, and other chronic infectious diseases. Our immunotherapies could potentially protect millions of people from sickness or death from diseases for which there are currently no adequate treatments.

Investment highlights

  • Phase II cervical dysplasia study induced regression of precancerous cervical disease and cleared HPV infection with robust T cell responses
  • Robust killer T cell immune responses reported in 3 of 4 patients with head and neck cancer associated with HPV
  • A major pharma partnership with MedImmune adds to validation of novel DNA immunotherapy technology's potential ability to prevent/treat cancers and infectious diseases
  • Working toward additional partnerships and collaborations
  • Almost $135M in non-dilutive third party R&D grants and expenditures since 2009
  • Operating capital through 4Q 2018
  • Synthetic DNA immunotherapies with proprietary delivery technology targeting diseases with multi-billion-dollar markets; designed to not just prevent but TREAT cancers and infectious diseases
  • Best-in-class T-cell immune responses displaying killing effect against target cells
  • Potential to break tolerance of immune system to cancerous cells
  • Universal antibody immune responses to protect against constantly changing viruses such as influenza
  • Favorable safety profile with no serious adverse events in hundreds of subjects to date
  • Global vaccine market expected to reach $84.44 billion by 2022, up from $32.05 billion in 2013
  • Global market for cancer therapies estimated to reach $225 billion by 2017
  • An estimated 70 monoclonal antibody products will be on the market by 2020 with combined global sales reaching $125 billion
  • Dominant global patent position
  • Management team and advisors are leaders in immunotherapies
  • Recognized with Vaccine Industry Excellence Awards for Best Therapeutic Vaccine (for HPV-associated diseases) and Best Early Stage Biotech Company at World Vaccine Congress.

While considered one of the most important medical developments, conventional vaccine technology has its boundaries of applicability. Our scientists are leveraging genomic engineering capabilities to design DNA-based immunotherapies that meet goals including:

  • Not just prevent, but treat diseases such as cancers and chronic infectious diseases such as HIV, hepatitis, and human papillomavirus-associated diseases;
  • More broadly protect against continually evolving strains of pathogens, a need exemplified by the challenge of protecting against new strains of influenza.

We believe our proprietary electroporation-based DNA delivery technology gives us a competitive edge. Electroporation delivers controlled, millisecond electrical pulses that cause the cell membrane to become temporarily permeable and enable increased uptake by 1,000 times or more of a biological material – such as a SynCon ® DNA immunotherapy - previously injected into local tissue.

The combination of our SynCon® immunotherapies delivered using electroporation has, in human studies, displayed a unique set of accomplishments that are unprecedented in the vaccine & immunotherapy world: efficacy data that provides evidence that a DNA-based immunotherapy technology can activate the immune system to fight chronic infections, pre-cancers — and ultimately, cancers; best-in-class T cell immune responses; initial evidence of immune responses against multiple unmatched virus strains from a single vaccine; the ability to facilitate multiple booster vaccinations without inducing unwanted immune responses against the vaccine; and a favorable safety profile without serious adverse events.

Regulatory approval of Inovio’s technology for use in humans would be a revolutionary step in the fight against cancers and infectious diseases.

Revolutionizing the fight against cancers & infectious diseases

Today, the potential exists to expand the benefits of immune stimulation to overcome cancers and challenging infectious diseases with unmet needs; and it is clear which specific technical advancements and medical outcomes must be achieved to fulfill this potential:

  • There is a need to better define and refine immune system targets in order to induce clinically relevant immune responses.
  • The generation of antibodies to prevent infection must be complemented by the ability to generate highly robust, targeted T-cell immune responses capable of treating established cancerous cells and chronic infections.
  • There is a need to develop antigen-specific cancer immunotherapies that are not dependent upon being patient specific and can activate – in the body! - functional, persistent, and durable T cell immune responses to help the body overcome its tolerance of its own self-made cancerous cells.
  • There is a need for new cancer treatments with more favorable safety profiles (less toxicity and side effects).
  • More efficient manufacturing would be beneficial.
  • We require technologies that cannot replicate and cause disease.
  • The “one bug, one drug” paradigm, which relies on the selection and targeting of a single pathogen strain, inadequately addresses influenza, HIV and other rapidly evolving viruses. Universal protection against multiple existing as well as newly emerging strains of a virus is imperative.

The rapidly advancing science of genomics along with an array of technical innovations make commercializing transformational technology with the above characteristics a realistic goal. The opportunity represented by such an achievement is substantial in its medical and commercial implications.

Our DNA-based immunotherapy technology platform has the potential to fulfill all these characteristics. Using this technology, Inovio’s goal is to develop transformative immunotherapy products that address the vast unmet needs in cancers and infectious diseases. With validating clinical efficacy data from our HPV caused cervical dysplasia study and best-in-class immune responses generated from human studies in multiple disease areas, our technology is making big strides toward this important goal.

Additional Information:

Inovio Pharmaceuticals Inc.


Inovio is taking immunotherapy to the next level in the fight against cancer and infectious diseases. We are the only immunotherapy company that has reported generating T cells in vivo in high quantity that are fully functional and whose killing capacity correlates with relevant clinical outcomes with a favorable safety profile. With an expanding portfolio of immune therapies, the company is advancing a growing preclinical and clinical stage product pipeline. Partners and collaborators include MedImmune, Regeneron Pharmaceuticals, Genentech, GeneOne Life Science, Plumbline Life Sciences, ApolloBio Corporation, The Wistar Institute, Laval University, University of Pennsylvania, Drexel University, DARPA, NIH, HIV Vaccines Trial Network, National Cancer Institute, and U.S. Military HIV Research Program. For more information, visit

Contact Information

Main Phone: +1 267 440-4200
Address: 660 West Germantown Pike
Address 2: Suite 110
State: PA
City / Town: Plymouth Meeting
Country: USA
Postal Code: 19462

Issuer Information

Exchange: NGS
CEO: J. Joseph Kim
Employees: 106
Issuer Type: CS - Common Stock
Sector/Industry: Cyclical
NAICS: Biological Produ
$ 5.45 $ 0.09 (1.68%)
Last Price 5.45 Change $ 0.09 Change % 1.68 Tick N/A
Bid 5.40 Bid Size 200.00 Ask 5.99 Ask Size 300.00
Open 5.30 High 5.56 Low 5.28 Prev Close 5.36
Last Trade Volume 838,819 52 Wk Hi 9.86 52 Wk Low 5.28
Market Cap 491.7 mi Ex-Div Date N/A Div Rate N/A Yield N/A
Shares 90,227,174.00 EPS (TTM) -1.08 PE Ratio N/A Exchange NGS
  Last 3 Mo Last 12 Mo
Number of Insider Trades 4 38
Number of Buys 2 29
Number of Sells 2 9
Net Activity -100866 504662
Last 10 Buys Shares
Morton C. Collins 1,000
Morton C. Collins 1,000
Morton C. Collins 1,000
Morton C. Collins 1,000
Morton C. Collins 1,000
Morton C. Collins 1,000
Niranjan Sardesai 1,000
Simon X. Benito 1,000
Angel Cabrera 1,000
Peter D. Kies 1,000
Last 10 Sell Shares
Simon X. Benito 1,000
  Current 1 Week Ago 2 Weeks Ago 3 Weeks Ago
High Target Price Estimate 31 31 31 31
Low Target Price Estimate 13 13 13 13
Mean Target Price Estimate 18.6 18.6 18.6 18.6
Standard Deviation 7.23 7.23 7.23 7.23
Date of Most Recent Estimate 08/09/16 07/17/16 07/17/16 08/19/16
  Current 1 Month Ago 2 Months Ago 3 Months Ago
Strong Buy 4 5 5 5
Moderate Buy 0 0 0 0
Hold 1 0 0 0
Moderate Sell 0 0 0 0
Strong Sell 0 0 0 0
Mean Rec. 1.4 1 1 1